Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Steroid bills

This article was originally published in The Tan Sheet

Executive Summary

House Government Reform Committee Chairman Tom Davis (R-Va.) will introduce a bill the week of May 23 proposing a uniform drug testing policy for major professional sports leagues, including MLB, the NFL and the NBA. Co-authored by Rep. Henry Waxman (D-Calif.) and Sen. John McCain (R-Ariz.), the legislation likely will suggest similar penalties to Rep. Cliff Stearns' (R-Fla.) Drug Free Sports Act, which calls for minimum two-year bans for first offenses and lifetime bans for second offenses. The House Government Reform Committee held a hearing on the NBA's drug policy on the heels of an NFL meeting in April (1"The Tan Sheet" May 2, 2005, p. 14)...

You may also be interested in...



NFL Supplement Policy Not Hindered By Lack Of GMPs – Tagliabue

The absence of dietary supplement good manufacturing practices has had minimal impact on the National Football League's steroid policy, according to Commissioner Paul Tagliabue

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel